About the Connective Tissue Disease - Interstitial Lung Disease (CTD-ILD) Working Group
Interstitial lung diseases (ILD), including those related to connective tissue disease (CTD), and idiopathic pulmonary fibrosis (IPF) carry high morbidity and mortality.
Great efforts are under way to develop and investigate meaningful treatments in the context of clinical trials. However, efforts have been challenged by a lack of validated outcome measures and by inconsistent use of measures in clinical trials.

Dinesh Khanna
Co-Chair

Susanna Proudman
Co-Chair
Athol Wells
Co-Chair

David Roofeh
Fellow
Technical Advisory Group Instrument Townhall Presentation from the CTD-ILD group of their Instruments for Lung Physiology
OMERACT Endorsed Core Domain Set Clinical Trials in Connective Tissue Disease - Interstitial Lung Disease (CTD-ILD)

Working Group Publications
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group
Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease–related Interstitial Lung Diseases
Working Group Members:
Alibaz-Oner, Fatma
Aydin, Sibel
Björk, María
Cam, Esen
Christensen, Robin
Dejaco, Christian
Direskeneli, Haner
Grayson, Peter
Hatemi, Gülen
Jayne, David
Kermani, Tanaz
Langford, Carol
Lanier, Georgia
Mackie, Sarah
Mahr, Alfred
Meara, Alexa
Milman, Nataliya
Ozguler, Yesim
Pagnoux, Christian
Robson, Joanna
Shea, Beverly
Tómasson, Gunnar
Merkel, Peter
Milman, Nataliya
Monti, Sara
Quinn, Kaitlin
Tugwell, Peter